Polyphenols, Fiber, and Blood Sugar

Evidence Review

Cholesterol Reduction — Human Randomized Trials

Zunft et al. (2003) conducted the landmark human trial on carob fiber and cholesterol [1]. In this randomized, double-blind, placebo-controlled study, 58 hypercholesterolemic volunteers consumed 15 g/day of insoluble carob pulp preparation or matched placebo in bread and fruit bars for six weeks.

Results:

• LDL cholesterol: reduced 10.5 ± 2.2% in the carob group versus placebo (p = 0.010)
• LDL:HDL ratio: decreased 7.9 ± 2.2% (p = 0.058, marginally significant)
• Triglycerides: reduced 11.3 ± 4.5% in female participants (p = 0.030); effect was sex-dependent
• HDL cholesterol: no significant change

The carob pulp used in this trial contained approximately 40% insoluble dietary fiber and 20% polyphenols. The authors attribute the effect to dual mechanisms: fiber binding bile acids and polyphenols inhibiting pancreatic lipase and suppressing fat absorption. No adverse effects were reported at this dose.

Ruiz-Roso et al. (2010) conducted a second human RCT confirming these findings [2]. In a crossover design with hypercholesterolemic subjects, consumption of insoluble carob fiber (standardized for polyphenol content) significantly reduced total cholesterol and LDL compared to placebo. The fiber fraction and polyphenol fraction were tested separately in animal components of the research program, with both contributing to lipid-lowering but the combination producing the largest effect — supporting the synergy hypothesis.

Limitations: both human trials are relatively small (fewer than 60 participants each), short-term (6 weeks), and used concentrated fiber preparations rather than culinary carob powder. Whether regular dietary use of carob powder at typical amounts produces similar effects is not established by these trials.

Diarrhea Treatment — Randomized Controlled Trial

Loeb et al. (1989) conducted a randomized, placebo-controlled trial in 41 infants aged 3–21 months with acute-onset diarrhea of bacterial and viral origin [3]. Infants received either tannin-rich carob pod powder (1.5 g/kg/day, maximum 15 g, providing 40% tannins or approximately 21% polyphenols and 26% dietary fiber) or placebo.

Results:

• Duration of diarrhea from admission: 2.0 ± 0.27 days (carob) vs. 3.75 ± 0.30 days (placebo), p < 0.001
• Normalization of body temperature, weight recovery, and cessation of vomiting all occurred more quickly in the carob group
• No adverse effects were reported; the preparation was well tolerated

The study is older (1989) and limited to infants; evidence in adults is less established. A less rigorous trial in adult travelers' diarrhea did not show benefit, suggesting that the effect may be more pronounced in infant-type diarrhea (often rotavirus-related), where tannin-mediated toxin binding and gut coating may be more important than in other etiologies.

Mechanism context: Condensed tannins form complexes with glycoproteins on the gut mucosal surface (an astringent effect), reduce intestinal permeability, and bind bacterial toxins directly. They also appear to inhibit rotavirus attachment to gut cells in vitro. This multi-target mechanism is consistent with the clinical results but has not been fully characterized in human mechanistic studies.

Pinitol and Blood Sugar — Randomized Trials

Kim et al. (2012) conducted a 12-week, randomized, placebo-controlled trial in 66 patients with type 2 diabetes mellitus [4]. Participants received either pinitol supplementation (600 mg twice daily) or placebo. Both groups continued standard diabetes care.

Results:

• HbA1c: significantly reduced in the pinitol group versus placebo (specific delta reported in full text)
• Fasting plasma glucose: significantly lower in the pinitol group
• HOMA-IR: significantly improved (lower insulin resistance index)
• Adipocytokine changes: pinitol group showed favorable shifts in adiponectin and leptin

This is directly relevant to carob because carob pods are among the richest known dietary sources of pinitol. The trial used isolated pinitol rather than whole carob, so the dose-per-food-amount translation requires estimation.

Lambert et al. (2018) examined a pinitol-enriched carob-pod-derived sweetener in subjects with impaired glucose tolerance (IGT) versus healthy controls [5]. Six weeks of consumption of the pinitol-enriched beverage (versus a sucrose-matched control) produced:

• Significant increases in IGF1BP-ALS (1.3-fold, involved in insulin secretion pathway) in IGT subjects
• Significant increases in complement C4A (1.83-fold) in IGT subjects
• In a parallel diabetic rat model, pinitol-fed animals showed significantly lower blood glucose than sucrose-fed animals and higher expression of intestinal GLUT2 (a glucose transporter)

This study used a carob-derived food product rather than isolated pinitol, making it more directly translatable to dietary use, though the subjects were consuming it as a sweetener replacement — not typical carob powder use.

Evidence Quality Assessment

Outcome	Evidence Level	Notes
LDL cholesterol reduction	Moderate	Two small RCTs; effect size ~10%; concentrated fiber preparations
Diarrhea duration (infants)	Moderate	Single good-quality RCT; strong effect; adults less studied
Blood sugar / insulin resistance (pinitol)	Moderate	RCT in T2D; effect established for pinitol; whole-carob data limited
Triglyceride reduction	Weak-Moderate	Seen in females in one RCT; not replicated broadly

Carob occupies an evidence tier comparable to many functional foods: real effects demonstrated in controlled conditions with plausible mechanisms, but trials are generally small and short-term. It is not a pharmaceutical intervention, but it is well ahead of many foods marketed for similar purposes, which lack human trial data entirely.